Company Overview
| Stock Name | Genscript Bio |
|---|---|
| Stock Code | 01548 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 全球廣受認同的生命科學研究與應用服務及產品供應商,提供涵蓋生命科學研究服務、生命科學研究目錄產品、臨床前藥物研發服務及工業合成生物產品的綜合服務及產品組合。 |
| Listing Date | 2015-12-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省南京市江寧科學園雍熙路28號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | genscript.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 1.31 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2015-12-22 to 2015-12-22 |
| Global Offering Shares | 400,000,000 shares |
| HK Public Offer Shares (Initial) | 40,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 360,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,600,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 5.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 524,000,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 49.03B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 2,400,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約6.2百萬美元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 50,800,000 |
| Listing Expenses / Funds Raised | ~9.69% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
USD
Income Statement
| Item | 2012 | 2013 | 2014 | 2015-06 |
|---|---|---|---|---|
| Revenue | 52,990 | 60,104 | 69,994 | 41,050 |
| Cost of sales | -17,547 | -21,846 | -25,896 | -14,192 |
| Gross profit | 35,443 | 38,258 | 44,098 | 26,858 |
| Other income and gains, net | 1,603 | 1,182 | 1,468 | 737 |
| Selling and distribution expenses | -10,339 | -12,813 | -15,538 | -8,357 |
| Administrative expenses | -15,018 | -16,855 | -21,446 | -11,325 |
| Operating profit | 11,274 | 7,866 | 8,247 | 7,896 |
| Net finance costs | -170 | -337 | -411 | 0 |
| Profit before tax | 11,104 | 7,529 | 7,836 | 7,896 |
| Income tax expense | -1,922 | -1,529 | -1,661 | -2,150 |
| Profit for the year | 9,182 | 6,000 | 6,175 | 5,746 |
| Profit attributable to owners | 9,182 | 6,000 | 6,175 | 5,746 |
Balance Sheet
| Item | 2012 | 2013 | 2014 | 2015-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 18,660 | 22,457 | 25,637 | 25,684 |
| Trade and bills receivables | 7,908 | 9,010 | 12,157 | 13,940 |
| Inventories | 1,244 | 1,404 | 1,777 | 2,136 |
| Total current assets | 30,099 | 38,561 | 43,792 | 43,768 |
| Total current liabilities | 30,252 | 29,885 | 29,188 | 23,739 |
| Total equity | 44,156 | 52,563 | 61,747 | 68,995 |
| Equity attributable to owners | 44,156 | 52,530 | 61,714 | 68,995 |
Cash Flow Statement
| Item | 2012 | 2013 | 2014 | 2015-06 |
|---|---|---|---|---|
| Net cash from operating activities | 9,190 | 12,024 | 12,206 | 9,274 |
| Net cash from investing activities | -7,317 | -10,914 | -9,114 | -1,121 |
| Net cash from financing activities | -99 | 1,988 | 395 | -8,178 |
| Net increase in cash | 1,774 | 3,098 | 3,487 | -25 |
| Depreciation of PP&E | 3,609 | 4,494 | 4,703 | 2,384 |
| Amortisation of intangible assets | 79 | 47 | 76 | 85 |
| Purchase of PP&E | -9,529 | -8,418 | -7,355 | -3,747 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 1.32 |
|---|---|
| First Day Open | HK$ 1.44 |
| First Day Change | 0.76% |
| First Day Volume | 45156000.0 |
| First Day Turnover | 63397600.0 |
| Use of Proceeds | 1、約30%或142.6百萬港元,將用于擴充現有生命科學研究與應用服務及產品組合;
2、約30%或142.6百萬港元,將用于擴充產能;
3、約3%或14.3百萬港元,將用于加強信息科技實力;
4、約12%或57.1百萬港元,將用于鞏固銷售及營銷團隊;
5、約15%或71.3百萬港元,將用于可能收購公司的權益或業務,此舉可補充現有業務、將我們的擴充策略與該等收購相融合,及增加收益及溢利;
6、約10%或47.5百萬港元,將用于補充周轉資金及用于一般公司用途。 |
Underwriting Syndicate
Sole Sponsor (1)
海通国际资本有限公司 CE ADQ859
Overall Coordinators (2)
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 合贸有限公司 | 108,730,000 HKD | — | 5.19% | — | 6 months | 2016-06-30 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 章方良 | — |
| Company Secretary | 黃慧玲 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 緊隨全球發售及資本化發行完成後,GS Corp持有908,502,024股,佔約56.78%;章方良、王魯泉及王燁作為一致行動人士各自持有約56.11%;吳女士持有約13.19%;KPCB China持有約14.58%。 |
|---|




